Home › Funds › BRADLEY FOSTER & SARGENT INC/CT › ABT

BRADLEY FOSTER & SARGENT INC/CT position in ABT

ABBOTT LABORATORIES · Health Care

BRADLEY FOSTER & SARGENT INC/CT reported holding 585,995 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$57.9M, representing 0.83% of its reported portfolio and ranking #29 among its reported holdings. BRADLEY FOSTER & SARGENT INC/CT has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)586.00K sh
Reported value held$57.91M
Portfolio Weight0.83%
First reportedQ3 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How BRADLEY FOSTER & SARGENT INC/CT's ABT position evolved

BRADLEY FOSTER & SARGENT INC/CT first disclosed a stake in ABT in Q3 2023 at 424,061 shares (US$46.2M). The position peaked in Q2 2025 at 829,317 shares, worth US$112.8M. Across 13 filings, BRADLEY FOSTER & SARGENT INC/CT increased the stake 7 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 585,995 shares valued at US$57.9M — a reduction of -7,850 shares quarter over quarter.. Notable position changes include a 27% trim in Q1 2026 (shares fell 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 424.06K $46.23M New
Q4 2023 452.52K $49.81M Add
Q1 2024 465.05K $52.86M Add
Q2 2024 508.81K $52.87M Add
Q3 2024 600.33K $68.44M Add
Q4 2024 635.75K $71.91M Add
Q1 2025 777.65K $103.16M Add
Q2 2025 829.32K $112.80M Add
Q3 2025 830.81K $111.28M Hold
Q4 2025 834.88K $104.60M Hold
Q1 2026 611.02K $62.73M Reduce
Q2 2026 593.85K $53.89M Reduce
Q3 2026 586.00K $57.91M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.65B), Charles Schwab Investment Management (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has BRADLEY FOSTER & SARGENT INC/CT held ABT?

BRADLEY FOSTER & SARGENT INC/CT has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is BRADLEY FOSTER & SARGENT INC/CT's current position in ABT?

As of Q3 2026, BRADLEY FOSTER & SARGENT INC/CT holds 586.00K shares of ABT (ABBOTT LABORATORIES), valued at $57.91M, representing 0.83% of its reported portfolio and ranking #29.

Has BRADLEY FOSTER & SARGENT INC/CT been buying or selling ABT?

In the latest 13F filing (Q3 2026), BRADLEY FOSTER & SARGENT INC/CT reduced its position in ABT. The position peaked in Q2 2025 at 829.32K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, Charles Schwab Investment Management, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.